Viking Therapeutics, Inc.

LSE (USD): Viking Therapeutics, Inc. (0VQA)

Last Price

34.56

Today's Change

+0.766 (2.26%)

Day's Change

34.40 - 35.75

Trading Volume

3,188

Overview

Market Cap

3 Billion

Shares Outstanding

109 Million

Avg Volume

10,491

Avg Price (50 Days)

38.31

Avg Price (200 Days)

21.29

PE Ratio

-47.15

EPS

-0.73

Earnings Announcement

21-Oct-2025

Previous Close

33.79

Open

35.75

Day's Range

34.4 - 35.75

Year Range

8.79 - 99.295

Trading Volume

3,248

Price Change Highlight

1 Day Change

2.27%

5 Day Change

3.23%

1 Month Change

25.26%

3 Month Change

18.15%

6 Month Change

3.72%

Ytd Change

-16.58%

1 Year Change

-33.29%

3 Year Change

867.53%

5 Year Change

449.44%

10 Year Change

134.15%

Max Change

134.15%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Pharmaceuticals, Biotechnology & Life Sciences

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

{uid}

{comment}

Just now

Post a Comment